Format

Send to

Choose Destination
Sleep. 2013 Apr 1;36(4):597-600. doi: 10.5665/sleep.2554.

Use of second-generation antipsychotic agents for sleep and sedation: a provider survey.

Author information

1
Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA. eric.hermes@yale.edu

Abstract

OBJECTIVES:

Anecdotal evidence suggests that second-generation antipsychotic agents are increasingly used to treat sleep problems. This study sought to quantify the proportion of new prescriptions for second-generation antipsychotic agents started for sleep/sedation and the correlates of such use.

DESIGN:

A cross-sectional survey of provider decision making at the time second-generation antipsychotic agents were prescribed, documenting the reasons for the medication, patient demographics, psychiatric and medical diagnoses, patient health characteristics, and provider background.

SETTING:

A single Veterans Affairs Medical Center over a 20-month period.

PARTICIPANTS:

Prescribers of second-generation antipsychotic agents.

INTERVENTIONS:

N/A.

RESULTS:

Seven hundred seven (32.2%) of 2,613 surveys indicated sleep/sedation was at least one reason for using a second-generation anti-psychotic agent, whereas for 266 (12.1%) it was the only reason. Quetiapine was most frequently prescribed overall as well as for sleep/sedation (47.0% and 73.6% respectively). Second-generation antipsychotic agent use for sleep/sedation was unrelated to sociodemographic characteristics, least likely in patients with schizophrenia or bipolar disorder, and most likely as a newly started second-generation antipsychotic agent.

CONCLUSION:

Sleep/sedation is a common reason given for new prescriptions of second-generation antipsychotic agents. Quetiapine is most frequently used for this purpose. A greater understanding of why providers use second-generation antipsychotic agents rather than safer and less costly alternatives for sleep problems may advance the development of interventions to reduce adverse effects.

KEYWORDS:

Atypical antipsychotics; decision-making; hypnotic; off-label; pharmacoepidemiology

PMID:
23565006
PMCID:
PMC3612245
DOI:
10.5665/sleep.2554
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center